查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1904659

生物技術創新與治療市場預測至2032年：按產品、治療領域、技術、應用、最終用戶和地區分類的全球分析

Biotechnology Innovations & Therapeutics Market Forecasts to 2032 - Global Analysis By Product, Therapeutic Area, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，全球生物技術創新和治療市場預計在 2025 年達到 12984 億美元，預計到 2032 年將達到 22542 億美元，在預測期內複合年成長率為 8.2%。

生物技術創新與治療業務板塊涵蓋透過開發和應用生物系統、生物體和分子過程，創造先進的醫療解決方案、藥物和治療方法。此板塊利用基因工程、分子生物學和生物資訊學，設計針對疾病的標靶治療，改善診斷方法，並提升患者照護。包括基因治療、個人化醫療、再生醫學和生技藥品在內的創新技術，旨在滿足尚未滿足的醫療需求。透過整合科學、技術和臨床研究，我們正在改變醫療保健，並為全球提供更精準、高效和永續的治療選擇。

基因工程的進展

基因工程的進步正推動生物技術創新和治療市場成長，其實現對基因的精準操控，進而開發標靶治療。 CRISPR、基因編輯和合成生物學等技術使研究人員能夠設計針對個別基因譜的客製化治療方法，提高療效並減少副作用。這些創新正在加速藥物研發，並推動新型生技藥品、再生醫學和個人化醫療解決方案的開發，最終改變全球醫療服務和病患預後。

高昂的研發和製造成本

高昂的研發和生產成本持續限制市場發展。開發先進治療方法、進行臨床試驗以及確保符合監管要求都需要大量的資金投入，這限制了中小企業的進入。生技藥品、基因療法和個人化藥物通常涉及複雜的生產流程，從而增加了整體成本。這些成本壁壘可能會延緩商業化進程，限制大規模應用，並為醫療服務提供者帶來挑戰，尤其是在新興市場，進而影響整體市場成長潛力。

個人化和精準醫療

個人化和精準醫療代表著巨大的市場成長機會。透過利用患者特異性的基因、分子和臨床數據，可以客製化治療方法，從而提高療效並最大限度地減少副作用。基因組學、生物標記和生物資訊學的創新正在推動腫瘤、罕見疾病和慢性病等領域的標靶治療策略。對個人化醫療日益成長的需求，加上科技的進步，為生技公司拓展產品組合、改善全球病患的治療效果提供了充滿希望的途徑。

可擴展性和製造障礙

規模化生產和製造壁壘對市場構成重大威脅。大規模生產複雜的生技藥品、基因療法和細胞療法需要精密的設備、嚴格的品管和嚴苛的監管合規。產能有限會導致供不應求、治療方法延遲和高成本。這些挑戰阻礙了市場的快速擴張，並限制了某些地區的市場准入，使得企業難以充分利用對創新療法日益成長的需求。

新冠疫情的感染疾病

新冠感染疾病對生物技術創新和治療市場產生了重大影響，加速了研究、資金籌措和新型治療方法的推出。疫苗研發、抗病毒藥物和診斷技術的進步展現了生物技術在危機應變中的巨大潛力。同時，供應鏈中斷、臨床試驗延誤和資源重新分配也影響了非新冠治療計劃。疫情凸顯了快速創新、與數位醫療整合以及全球合作的重要性，為生物技術公司應對未來醫療保健挑戰奠定了基礎。

預計在預測期內，腫瘤治療領域將佔據最大的市場佔有率。

由於癌症發病率不斷上升以及對標靶治療的需求日益成長，腫瘤治療領域預計在預測期內將佔據最大的市場佔有率。免疫療法、基因療法和個人化癌症治療方案的創新正在提高患者的生存率和生活品質。先進的診斷技術和精準醫療正在推動早期檢測和個人化治療。持續的研發投入，以及人們日益增強的健康意識和醫療基礎設施的不斷完善，共同助力腫瘤治療領域在全球市場確立了主導地位。

預計在預測期內，DNA定序領域將呈現最高的複合年成長率。

由於新一代定序技術的快速發展，預計在預測期內，DNA定序領域將達到最高成長率。成本降低、結果更快、準確性更高，正推動其在基因組研究和臨床診斷領域的應用。定序技術能夠識別基因突變和治療標靶，從而支持精準醫療。腫瘤學和微生物組研究領域日益成長的應用，以及不斷提升的檢測能力，正在推動全球DNA定序市場強勁成長。

比最大的地區

由於患者群體不斷成長和生物技術基礎設施不斷完善，亞太地區預計將在預測期內佔據最大的市場佔有率。政府支持力度的加大、新興生物技術中心的湧現以及與全球企業的合作，正在推動治療和生技藥品領域的創新。該地區對研究和臨床試驗的日益重視以及先進技術的應用，正在加速市場滲透。公眾意識的提高、醫療保健服務的改善以及為降低醫療成本所做的努力，進一步鞏固了亞太地區在全球市場的主導地位。

年複合成長率最高的地區

在預測期內，北美地區預計將呈現最高的複合年成長率，這主要得益於其強大的生物技術生態系統和先進的研究基礎設施。眾多大型生物技術公司的存在、創業投資資金籌措以及開創性的臨床試驗正在推動基因療法、個人化醫療和生技藥品領域的快速創新。技術進步、慢性病盛行率的上升以及對最先進治療的早期應用將推動市場成長。北美地區的策略聯盟和醫療保健投資使其成為生物技術創新和治療領域的高成長地區。

免費客製化服務

購買此報告的客戶可享有以下免費自訂選項之一：

  • 公司概況
    • 最多三家新增市場參與企業進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，對主要國家進行市場估算和預測，並計算複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 從產品系列、地域覆蓋範圍和策略聯盟等方面對主要參與企業進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生物技術創新和治療市場（按產品分類）

  • 生物製藥
    • 單株抗體
    • 細胞和基因治療
    • 疫苗
    • 重組蛋白
  • 生物加工設備及耗材
  • 生物資訊工具平台

6. 全球生物技術創新與治療市場（依治療領域分類）

  • 腫瘤學
  • 自體免疫疾病
  • 神經病學
  • 罕見疾病和遺傳疾病
  • 循環系統疾病
  • 感染疾病

7. 全球生物技術創新與治療市場（依技術分類）

  • DNA定序
  • 合成生物學
  • 重組DNA技術
  • CRISPR和基因編輯
  • 奈米生物技術
  • 幹細胞技術
  • 細胞培養技術
  • 組織工程與再生醫學

8. 全球生物技術創新和治療市場（按應用分類）

  • 健康與紅色生物技術
    • 基因治療
    • 診斷
    • 個人化醫療
    • 再生醫學
  • 食品和農業生物技術
    • 基因改造作物
    • 動物生物技術
  • 工業生物技術
  • 環境生物技術

9. 全球生物技術創新和治療市場（按最終用戶分類）

  • 生物製藥生物技術公司
  • 學術和研究機構
  • 契約製造組織（CMO）
  • 受託研究機構（CRO）
  • 醫院診所

10. 全球生物技術創新與治療市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Gilead Sciences
  • Novo Nordisk
  • Biogen
  • Alnylam Pharmaceuticals
  • Moderna
  • Vertex Pharmaceuticals
  • Roche
  • BioNTech
  • Johnson & Johnson
  • Siemens Healthineers
  • Pfizer
  • Amgen
  • Sanofi
  • Novartis
  • AstraZeneca
Product Code: SMRC32975

According to Stratistics MRC, the Global Biotechnology Innovations & Therapeutics Market is accounted for $1,298.4 billion in 2025 and is expected to reach $2,254.2 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Biotechnology Innovations & Therapeutics encompass the development and application of biological systems, organisms, and molecular processes to create advanced medical solutions, drugs, and therapies. This field leverages genetic engineering, molecular biology, and bioinformatics to design targeted treatments for diseases, improve diagnostics, and enhance patient care. Innovations include gene therapies, personalized medicine, regenerative medicine, and biologics, aiming to address unmet medical needs. By combining science, technology, and clinical research, it transforms healthcare, offering more precise, effective, and sustainable therapeutic options worldwide.

Market Dynamics:

Driver:

Advances in Genetic Engineering

Advances in genetic engineering are driving the growth of the Biotechnology Innovations & Therapeutics market by enabling precise manipulation of genes to develop targeted therapies. Techniques such as CRISPR, gene editing, and synthetic biology allow researchers to design treatments tailored to individual genetic profiles, improving efficacy and reducing side effects. These innovations are accelerating drug discovery, enabling the creation of novel biologics, regenerative therapies, and personalized medicine solutions, ultimately transforming healthcare delivery and patient outcomes globally.

Restraint:

High R&D & Production Costs

High research, development, and production costs continue to restrain the market. Developing advanced therapies, conducting clinical trials, and ensuring regulatory compliance require significant financial investment, limiting accessibility for smaller companies. Biologics, gene therapies, and personalized medicines often involve complex manufacturing processes, adding to overall expenses. These cost barriers can delay commercialization, restrict large-scale adoption, and pose challenges for healthcare providers, particularly in emerging markets, affecting the overall market growth potential.

Opportunity:

Personalized & Precision Medicine

Personalized and precision medicine represents a significant growth opportunity in the market. By leveraging patient-specific genetic, molecular, and clinical data, therapies can be tailored to achieve higher efficacy and minimize adverse effects. Innovations in genomics, biomarkers, and bioinformatics facilitate targeted treatment strategies across oncology, rare diseases, and chronic conditions. The rising demand for individualized care, combined with technological advancements, provides a promising avenue for biotech companies to expand their portfolios and enhance global patient outcomes.

Threat:

Scalability & Manufacturing Barriers

Scalability and manufacturing barriers pose a critical threat to the market. Producing complex biologics, gene therapies, and cell-based treatments at commercial scale involves sophisticated equipment, strict quality control, and stringent regulatory compliance. Limitations in production capacity can lead to supply shortages, delayed therapy availability, and high costs. These challenges hinder rapid market expansion and restrict access in certain regions, making it difficult for companies to fully capitalize on the growing demand for innovative therapeutic solutions.

Covid-19 Impact:

The Covid-19 pandemic has significantly influenced the Biotechnology Innovations & Therapeutics market by accelerating research, funding, and adoption of novel therapies. Vaccine development, antiviral drugs, and diagnostic advancements showcased biotechnology's potential in crisis response. Simultaneously, supply chain disruptions, clinical trial delays, and resource reallocations impacted non-Covid therapeutic projects. The pandemic highlighted the importance of rapid innovation, digital health integration, and global collaboration, positioning biotech companies to address future healthcare challenges.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to account for the largest market share during the forecast period, due to rising cancer prevalence and the demand for targeted treatments. Innovations in immunotherapies, gene therapies, and personalized oncology solutions are improving patient survival and quality of life. Advanced diagnostics and precision medicine enable early detection and tailored therapies. Continuous investment in research, coupled with increasing awareness and healthcare infrastructure development, positions the oncology segment as a dominant force within the market globally.

The DNA sequencing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the DNA sequencing segment is predicted to witness the highest growth rate, due to rapid advancements in next-generation sequencing technologies. Reduced costs, faster turnaround times, and improved accuracy are fueling adoption across genomics research and clinical diagnostics. Sequencing enables identification of genetic variations and therapeutic targets, supporting precision healthcare. Growing applications in oncology and microbiome research, combined with expanding laboratory capabilities, are driving robust growth in the DNA sequencing segment within the global market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to growing patient populations, and expanding biotechnology infrastructure. Increased government support, emerging biotech hubs, and collaborations with global companies are fostering innovation in therapeutics and biologics. The region's focus on research, clinical trials, and adoption of advanced technologies enhances market penetration. Rising awareness, improving healthcare access, and affordability initiatives further strengthen the dominance of Asia Pacific in the market globally.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust biotechnology ecosystem and advanced research infrastructure. The presence of leading biotech companies, venture capital funding, and pioneering clinical trials fosters rapid innovation in gene therapies, personalized medicine, and biologics. Technological advancements, increasing prevalence of chronic and diseases, and early adoption of cutting-edge therapies drive market growth. North America's strategic collaborations and healthcare investments position it as a high-growth region in Biotechnology Innovations & Therapeutics.

Key players in the market

Some of the key players in Biotechnology Innovations & Therapeutics Market include Gilead Sciences, Novo Nordisk, Biogen, Alnylam Pharmaceuticals, Moderna, Vertex Pharmaceuticals, Roche, BioNTech, Johnson & Johnson, Siemens Healthineers, Pfizer, Amgen, Sanofi, Novartis and AstraZeneca.

Key Developments:

In November 2025, Siemens Healthineers introduced Syngo Carbon 2.0, an upgraded enterprise imaging platform. The launch integrates multimodal imaging data, AI-powered workflow automation, and cloud-based collaboration, designed to streamline radiology operations and improve diagnostic accuracy across global healthcare systems.

In October 2025, Siemens Healthineers expanded its collaboration with Varian and multiple oncology centers to accelerate precision therapy solutions. The joint venture integrates imaging, radiation therapy, and AI-driven planning tools, aiming to improve cancer treatment outcomes and strengthen Siemens' leadership in oncology care.

Products Covered:

  • Biopharmaceuticals
  • Bioprocess Equipment & Consumables
  • Bioinformatics Tools & Platforms

Therapeutic Areas Covered:

  • Oncology
  • Autoimmune Disorders
  • Neurology
  • Rare & Genetic Diseases
  • Cardiovascular Diseases
  • Infectious Diseases

Technologies Covered:

  • DNA Sequencing
  • Synthetic Biology
  • Recombinant DNA Technology
  • CRISPR & Gene Editing
  • Nanobiotechnology
  • Stem Cell Technology
  • Cell Culture Technology
  • Tissue Engineering & Regeneration

Applications Covered:

  • Health & Red Biotechnology
  • Food & Agriculture Biotechnology
  • Industrial Biotechnology
  • Environmental Biotechnology

End Users Covered:

  • Biopharma & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)
  • Hospitals & Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biotechnology Innovations & Therapeutics Market, By Product

  • 5.1 Introduction
  • 5.2 Biopharmaceuticals
    • 5.2.1 Monoclonal Antibodies
    • 5.2.2 Cell & Gene Therapies
    • 5.2.3 Vaccines
    • 5.2.4 Recombinant Proteins
  • 5.3 Bioprocess Equipment & Consumables
  • 5.4 Bioinformatics Tools & Platforms

6 Global Biotechnology Innovations & Therapeutics Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Autoimmune Disorders
  • 6.4 Neurology
  • 6.5 Rare & Genetic Diseases
  • 6.6 Cardiovascular Diseases
  • 6.7 Infectious Diseases

7 Global Biotechnology Innovations & Therapeutics Market, By Technology

  • 7.1 Introduction
  • 7.2 DNA Sequencing
  • 7.3 Synthetic Biology
  • 7.4 Recombinant DNA Technology
  • 7.5 CRISPR & Gene Editing
  • 7.6 Nanobiotechnology
  • 7.7 Stem Cell Technology
  • 7.8 Cell Culture Technology
  • 7.9 Tissue Engineering & Regeneration

8 Global Biotechnology Innovations & Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Health & Red Biotechnology
    • 8.2.1 Gene Therapy
    • 8.2.2 Diagnostics
    • 8.2.3 Personalized Medicine
    • 8.2.4 Regenerative Medicine
  • 8.3 Food & Agriculture Biotechnology
    • 8.3.1 GM Crops
    • 8.3.2 Animal Biotechnology
  • 8.4 Industrial Biotechnology
  • 8.5 Environmental Biotechnology

9 Global Biotechnology Innovations & Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Biopharma & Biotechnology Companies
  • 9.3 Academic & Research Institutes
  • 9.4 Contract Manufacturing Organizations (CMOs)
  • 9.5 Contract Research Organizations (CROs)
  • 9.6 Hospitals & Clinics

10 Global Biotechnology Innovations & Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Gilead Sciences
  • 12.2 Novo Nordisk
  • 12.3 Biogen
  • 12.4 Alnylam Pharmaceuticals
  • 12.5 Moderna
  • 12.6 Vertex Pharmaceuticals
  • 12.7 Roche
  • 12.8 BioNTech
  • 12.9 Johnson & Johnson
  • 12.10 Siemens Healthineers
  • 12.11 Pfizer
  • 12.12 Amgen
  • 12.13 Sanofi
  • 12.14 Novartis
  • 12.15 AstraZeneca

List of Tables

  • Table 1 Global Biotechnology Innovations & Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Biotechnology Innovations & Therapeutics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Biotechnology Innovations & Therapeutics Market Outlook, By Biopharmaceuticals (2024-2032) ($MN)
  • Table 4 Global Biotechnology Innovations & Therapeutics Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 5 Global Biotechnology Innovations & Therapeutics Market Outlook, By Cell & Gene Therapies (2024-2032) ($MN)
  • Table 6 Global Biotechnology Innovations & Therapeutics Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 7 Global Biotechnology Innovations & Therapeutics Market Outlook, By Recombinant Proteins (2024-2032) ($MN)
  • Table 8 Global Biotechnology Innovations & Therapeutics Market Outlook, By Bioprocess Equipment & Consumables (2024-2032) ($MN)
  • Table 9 Global Biotechnology Innovations & Therapeutics Market Outlook, By Bioinformatics Tools & Platforms (2024-2032) ($MN)
  • Table 10 Global Biotechnology Innovations & Therapeutics Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 11 Global Biotechnology Innovations & Therapeutics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 12 Global Biotechnology Innovations & Therapeutics Market Outlook, By Autoimmune Disorders (2024-2032) ($MN)
  • Table 13 Global Biotechnology Innovations & Therapeutics Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 14 Global Biotechnology Innovations & Therapeutics Market Outlook, By Rare & Genetic Diseases (2024-2032) ($MN)
  • Table 15 Global Biotechnology Innovations & Therapeutics Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 16 Global Biotechnology Innovations & Therapeutics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 17 Global Biotechnology Innovations & Therapeutics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 18 Global Biotechnology Innovations & Therapeutics Market Outlook, By DNA Sequencing (2024-2032) ($MN)
  • Table 19 Global Biotechnology Innovations & Therapeutics Market Outlook, By Synthetic Biology (2024-2032) ($MN)
  • Table 20 Global Biotechnology Innovations & Therapeutics Market Outlook, By Recombinant DNA Technology (2024-2032) ($MN)
  • Table 21 Global Biotechnology Innovations & Therapeutics Market Outlook, By CRISPR & Gene Editing (2024-2032) ($MN)
  • Table 22 Global Biotechnology Innovations & Therapeutics Market Outlook, By Nanobiotechnology (2024-2032) ($MN)
  • Table 23 Global Biotechnology Innovations & Therapeutics Market Outlook, By Stem Cell Technology (2024-2032) ($MN)
  • Table 24 Global Biotechnology Innovations & Therapeutics Market Outlook, By Cell Culture Technology (2024-2032) ($MN)
  • Table 25 Global Biotechnology Innovations & Therapeutics Market Outlook, By Tissue Engineering & Regeneration (2024-2032) ($MN)
  • Table 26 Global Biotechnology Innovations & Therapeutics Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global Biotechnology Innovations & Therapeutics Market Outlook, By Health & Red Biotechnology (2024-2032) ($MN)
  • Table 28 Global Biotechnology Innovations & Therapeutics Market Outlook, By Gene Therapy (2024-2032) ($MN)
  • Table 29 Global Biotechnology Innovations & Therapeutics Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 30 Global Biotechnology Innovations & Therapeutics Market Outlook, By Personalized Medicine (2024-2032) ($MN)
  • Table 31 Global Biotechnology Innovations & Therapeutics Market Outlook, By Regenerative Medicine (2024-2032) ($MN)
  • Table 32 Global Biotechnology Innovations & Therapeutics Market Outlook, By Food & Agriculture Biotechnology (2024-2032) ($MN)
  • Table 33 Global Biotechnology Innovations & Therapeutics Market Outlook, By GM Crops (2024-2032) ($MN)
  • Table 34 Global Biotechnology Innovations & Therapeutics Market Outlook, By Animal Biotechnology (2024-2032) ($MN)
  • Table 35 Global Biotechnology Innovations & Therapeutics Market Outlook, By Industrial Biotechnology (2024-2032) ($MN)
  • Table 36 Global Biotechnology Innovations & Therapeutics Market Outlook, By Environmental Biotechnology (2024-2032) ($MN)
  • Table 37 Global Biotechnology Innovations & Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 38 Global Biotechnology Innovations & Therapeutics Market Outlook, By Biopharma & Biotechnology Companies (2024-2032) ($MN)
  • Table 39 Global Biotechnology Innovations & Therapeutics Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 40 Global Biotechnology Innovations & Therapeutics Market Outlook, By Contract Manufacturing Organizations (CMOs) (2024-2032) ($MN)
  • Table 41 Global Biotechnology Innovations & Therapeutics Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 42 Global Biotechnology Innovations & Therapeutics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.